Table 2.

MiRNA-based preclinical studies and clinical trials.

MiRNAs	Target	Delivery Vehicle	Approach	Tumor Type	Results	Ref.
Preclinical Trials
Let-7b	Kras	Adenovirus	Intranasal	NSCLC	66% reduction in orthotopic tumor burden; Reduced xenograft growth	[10]
MiR-29b	CDK6	Cationic lipoplexes	Caudal	NSCLC	60% xenograft growth inhibition	[152]
MiR-200c	PRDX2 GABP/Nrf2 SESN1	Amphoteric liposome	Subcutaneous	NSCLC	MiR-200c plus radiotherapy delayed xenograft growth	[153]
MiR-34a and Let-7b	Kras p53	Neutral lipid emulsion	Caudal	NSCLC	40% increased survival with combination or miR-34a alone	[28]
MiR-126	PTEN/PI3K/AKT	231-Exosome	Intravenous	NSCLC	Inhibit the formulation of lung metastasis	[154]
MiR-101	BCL6	AD-MSC-EVs	Caudal	Osteosarcoma	Inhibit the formulation of lung metastasis	[155]
MiR-21-5p	BTG2	UTMD	Caudal	NSCLC	Reduced the size and volume of xenograft growth	[156]
Clinical Trials
MiR-16	EGFR	EDVs	Intravenous	NSCLC MPM	5 × 109 TargomiRs once weekly was the maximum tolerated dose.	[160]
MiR-34	Kras P53 PDGFR CDK4 etc.	Liposome	Intravenous	Solid tumors Hematologic malignancies	Trial was closed early due to serious immune-mediated AEs	[12]